Payment overview · 2025
General Payments
$730.31
41 reported records · 17 companies
Healthcare provider profile · identity verified
Mohammad Mousa, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · MONROE, LA · NPI 1841383221
Verified facts
What the public records show
CMS Open Payments records show Mohammad Mousa, M.D. received $730.31 in general payments during 2025 across 41 reported records.
ACADIA Pharmaceuticals Inc accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Korlym, Mounjaro, Nuplazid, Veozah.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Nuplazid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Veozah by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 523 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $160.51 | 22.0% | 14 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $152.14 | 20.8% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.47 | 7.0% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $42.53 | 5.8% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $39.87 | 5.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.69 | 5.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $33.76 | 4.6% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $32.96 | 4.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.62 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $23.11 | 3.2% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $22.96 | 3.1% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.19 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.71 | 2.6% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $18.32 | 2.5% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $18.16 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.75 | 2.2% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $15.56 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $730.31 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $160.51 | 14 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $152.14 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.47 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $39.87 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $33.76 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $32.96 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $32.96 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $32.96 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $15.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 106 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 523 | exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
73 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
396 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
523 | 88 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 17 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
106 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
248 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1140 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 926 | 100 |
| Gabapentin | Gabapentin | 725 | 95 |
| Potassium Chloride | Potassium Chloride | 714 | 83 |
| Eliquis | Apixaban | 710 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 82 |
| Famotidine | Famotidine | 596 | 65 |
| Donepezil Hcl | Donepezil Hcl | 546 | 52 |
| Mounjaro | Tirzepatide | 523 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 499 | 67 |
| Furosemide | Furosemide | 467 | 80 |
| Memantine Hcl | Memantine Hcl | 453 | 50 |
| Jardiance | Empagliflozin | 396 | 52 |
| Trazodone Hcl | Trazodone Hcl | 371 | 48 |
| Ozempic | Semaglutide | 368 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 350 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 330 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 36 |
| Lisinopril | Lisinopril | 302 | 51 |
| Metformin Hcl | Metformin Hcl | 298 | 54 |
| Sertraline Hcl | Sertraline Hcl | 290 | 41 |
| Tradjenta | Linagliptin | 283 | 25 |
| Losartan Potassium | Losartan Potassium | 268 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 39 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 248 | 12 |
| Mirtazapine | Mirtazapine | 246 | 29 |
| Carvedilol | Carvedilol | 221 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 206 | 26 |
| Levetiracetam | Levetiracetam | 201 | 24 |
| Entresto | Sacubitril/Valsartan | 175 | 12 |
| Topiramate | Topiramate | 174 | 27 |
| Montelukast Sodium | Montelukast Sodium | 171 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 158 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 155 | 31 |
| Divalproex Sodium | Divalproex Sodium | 153 | 24 |
| Prednisone | Prednisone | 152 | 27 |
| Buspirone Hcl | Buspirone Hcl | 150 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 24 |
| Finasteride | Finasteride | 147 | 16 |
| Allopurinol | Allopurinol | 141 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 17 |
| Simvastatin | Simvastatin | 130 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 128 | 38 |
| Spironolactone | Spironolactone | 123 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 118 | 15 |
| Glimepiride | Glimepiride | 118 | 22 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 117 | 20 |
| Omeprazole | Omeprazole | 113 | 23 |
| Farxiga | Dapagliflozin Propanediol | 109 | 13 |
| Ingrezza | Valbenazine Tosylate | 106 | 12 |
| Novolog | Insulin Aspart | 106 | 33 |
| Colchicine | Colchicine | 105 | 14 |
| Meloxicam | Meloxicam | 105 | 30 |
| Latanoprost | Latanoprost | 104 | 19 |
| Methimazole | Methimazole | 98 | 19 |
| Olanzapine | Olanzapine | 98 | 13 |
| Sucralfate | Sucralfate | 96 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 95 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | suppressed |
| Azithromycin | Azithromycin | 93 | 70 |
| Cinacalcet Hcl | Cinacalcet Hcl | 93 | 19 |
| Januvia | Sitagliptin Phosphate | 91 | suppressed |
| Glipizide | Glipizide | 89 | 17 |
| Meclizine Hcl | Meclizine Hcl | 86 | 12 |
| Trulicity | Dulaglutide | 82 | 17 |
| Rivastigmine | Rivastigmine | 81 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 79 | suppressed |
| Aripiprazole | Aripiprazole | 78 | suppressed |
| Risperidone | Risperidone | 78 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 23 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 75 | 25 |
| Linzess | Linaclotide | 75 | 18 |
| Lovastatin | Lovastatin | 73 | suppressed |
| Myrbetriq | Mirabegron | 73 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 71 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 11 |
| Xarelto | Rivaroxaban | 70 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | suppressed |
| Primidone | Primidone | 64 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 64 | suppressed |
| Carbamazepine | Carbamazepine | 62 | suppressed |
| Amantadine | Amantadine Hcl | 61 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 61 | 20 |
| Baclofen | Baclofen | 61 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | suppressed |
| Novolog Flexpen | Insulin Aspart | 59 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 58 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Bumetanide | Bumetanide | 54 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 41 |
| Nuplazid | Pimavanserin Tartrate | 52 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 14 |
| Kerendia | Finerenone | 49 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 48 | suppressed |
| Ranolazine Er | Ranolazine | 47 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 24 |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 45 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Sotalol | Sotalol Hcl | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | 23 |
| Gemtesa | Vibegron | 43 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | 14 |
| Insulin Lispro | Insulin Lispro | 43 | 22 |
| Ondansetron Odt | Ondansetron | 43 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | suppressed |
| Lactulose | Lactulose | 40 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 16 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 38 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 16 |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Methocarbamol | Methocarbamol | 37 | suppressed |
| Pentoxifylline | Pentoxifylline | 37 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 29 |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 35 | suppressed |
| Armour Thyroid | Thyroid,pork | 34 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Humulin R | Insulin Regular, Human | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 18 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Anastrozole | Anastrozole | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 31 | suppressed |
| Xifaxan | Rifaximin | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Humalog | Insulin Lispro | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Timolol Maleate | Timolol Maleate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Entacapone | Entacapone | 28 | suppressed |
| Novolin R | Insulin Regular, Human | 28 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 28 | 21 |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Dalfampridine Er | Dalfampridine | 26 | suppressed |
| Nystatin | Nystatin | 26 | 16 |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 22 |
| Insulin Aspart | Insulin Aspart | 24 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 19 | 11 |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Glucagon Emergency Kit | Glucagon | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 18 | 14 |
| Metolazone | Metolazone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 14 | suppressed |
| Korlym | Mifepristone | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Mitigare | Colchicine | 13 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Darunavir | Darunavir | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $730.31 · 41 records | ACADIA Pharmaceuticals Inc | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Flector, GIMOTI, INGREZZA, Korlym, Licart, MOUNJARO, NP Thyroid 60, NUPLAZID, Omnipod, REXULTI, TEPEZZA, TWIIST, Tirosint, VYKAT XR, Veozah, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error